$Novo Nordisk AS(NVO.US) plunged -14% hitting a new four-year low and $Eli Lilly(LLY.US) rose +3% pre-mkt after Novo’s next generation CagriSema weight loss drug showed inferiority to LLY’s Zepbound in Phase Three obesity trials after 84 weeks.
The 809-patient trial evaluated Novo Nordisk’s once-weekly, subcutaneous CagriSema, which combines 2.4-milligram cagrilintide and 2.4-mg semaglutide, against 15-mg tirzepatide, the active ingredient in LLY’s Zepbound weight loss treatment. Headline results showed that CagriSema delivered 23% weight loss versus 25.5% for tirzepatide after 84 weeks. Under the treatment regimen estimand (regardless of treatment adherence), weight loss was 20.2% for CagriSema and 23.6% for tirzepatide. Novo Nordisk said it expects to begin a higher-dose phase 3 trial of CagriSema in the second half of 2026.The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments